Evidence map›Paper›PMID 31206214›Full record

ArticleHepatology (Baltimore, Md.)2019

Dose and Duration of Aspirin Use to Reduce Incident Hepatocellular Carcinoma.

Naoto Fujiwara, Amit G Singal, Yujin Hoshida

Open access · greenAbstract readComment
PubMed Full text at PMC Publisher
In one paragraph

Article in Hepatology (Baltimore, Md.), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.5field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Observational
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 2 countries.

Naoto FujiwaraDivision of Digestive and Liver Diseases, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX.
Amit G SingalDivision of Digestive and Liver Diseases, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX.
Yujin HoshidaDivision of Digestive and Liver Diseases, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX.
The University of Texas Southwestern Medical Center · USUniversity of Tokyo Hospital · JP

Funding

Reverse-engineering precision liver cancer chemopreventionR01CA233794 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI HOSHIDA, YUJIN · 2019 to 2023
$3.5M
Glycopathology of HCC: identification of the source cells of serum fucosylationU01CA226052 · NCI · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI DRAKE, RICHARD R., HOSHIDA, YUJIN · 2019 to 2023
$2.8M
Molecular Prognostic Indicators in Liver Cirrhosis and CancerR01DK099558 · NIDDK · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI HOSHIDA, YUJIN · 2013 to 2016
$2.6M
(PQB6) Accurate Comparative Genome-wide Analysis of Primary Tumors and MetastasesR21CA180016 · NCI · UNIVERSITY OF VIRGINIA · PI PEMBERTON, LUCY F, WOTTON, DAVID · 2013 to 2014
$373k
Cancer Prevention and Research Institute of Texas RR180016European Research Council 671231European Union ERC-2014-AdG-671231 HEPCIRIrma T. Hirschl TrustNCI NIH HHS R01 CA233794NCI NIH HHS U01 CA226052NIDDK NIH HHS R01 DK099558Uehara Memorial FoundationU.S. Department of Defense W81XWH-16-1-0363
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Carcinoma, HepatocellularLiver NeoplasmsAnti-Inflammatory Agents, Non-SteroidalAspirinHumansRisk FactorsAnti-Inflammatory Agents, Non-SteroidalAspirin

Identifiers

PMID31206214
PMCPMC6885093
OpenAlexW2950675535

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.